|
·
|
Effective against all known influenza strains of these types
|
|
·
|
In vitro assays have shown that TAMIFLU inhibits the neuraminidases of both influenza A and B viruses and prevents their replication
|
|
·
|
Efficacy was shown in clinical studies conducted worldwide in which the predominant infections were type A and a small number of patients had influenza type B
|
|
·
|
Achieves and maintains plasma concentrations above the antiviral IC50 for laboratory strains of influenza A and B for 12 hours after a single 75 mg dose9
|
|
·
|
The relationship between the in vitro antiviral activity in cell culture and the inhibition of influenza virus replication in humans has not been established
|
|
·
|
Statistically and clinically significant benefits were consistently achieved in studies worldwide
|
|
·
|
In an ongoing study of Tamiflu in otherwise healthy elderly patients >65 years (n=168), there was a reduction in influenza duration similar to that seen in younger adults
|
|
·
|
Fever is a hallmark symptom of influenza that is debilitating for patients
|
|
·
|
Challenge studies support A and B antiviral activity in volunteers who received Tamiflu or placebo shortly after influenza virus inoculation
|
|
·
|
One 75 mg capsule twice daily for 5 days
|
|
·
|
A familiar route of administration
|
|
·
|
No patient training required
|
|
·
|
Treatment should begin within 2 days of symptom onset
|
|
·
|
May be taken with or without food
|